Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4861132 | 0.99 | SIGMAR1 (0.43) | SIGMAR1BCHEACHECHRM2CHRM1 | |
| SCHEMBL13988069 | 0.88 | KMT2A (0.38) | SIGMAR1BCHEACHEDRD2 | |
| SCHEMBL6035468 | 0.88 | SIGMAR1 (0.44) | SIGMAR1BCHEACHECHRM2CHRM1 | |
| SCHEMBL6035073 | 0.87 | MCHR1 (0.38) | BCHEACHECHRM1DRD2 | |
| Hydrochloric Acid SCHEMBL4861295 | 0.87 | SIGMAR1 (0.43) | SIGMAR1BCHEACHECHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL4857673 | 0.86 | MCHR1 (0.38) | BCHEACHECHRM1DRD2 | |
| SCHEMBL6034199 | 0.85 | THRA (0.46) | SIGMAR1ACHE | |
| SCHEMBL13987735 | 0.84 | SIGMAR1 (0.42) | SIGMAR1BCHEACHECHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL4853622 | 0.84 | THRA (0.45) | SIGMAR1ACHE | |
| Hydrochloric Acid SCHEMBL5984191 | 0.83 | SIGMAR1 (0.42) | SIGMAR1BCHEACHECHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | claimed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | SIGMAR1 2780/4885BCHE 23/4885ACHE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.